Home » Stocks » Kura Oncology

Kura Oncology, Inc. (KURA)

Stock Price: $17.16 USD 0.23 (1.36%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 779.69M
Revenue (ttm) n/a
Net Income (ttm) -68.41M
Shares Out 55.90M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $17.16
Previous Close $16.93
Change ($) 0.23
Change (%) 1.36%
Day's Open 16.86
Day's Range 16.72 - 17.42
Day's Volume 408,882
52-Week Range 6.35 - 20.00

More Stats

Market Cap 779.69M
Enterprise Value 570.05M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 55.90M
Float 40.46M
EPS (basic) -1.56
EPS (diluted) -1.56
FCF / Share -1.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.81M
Short Ratio 6.42
Short % of Float 8.70%
Beta 2.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.61
Revenue n/a
Operating Income -72.78M
Net Income -68.41M
Free Cash Flow -60.84M
Net Cash 209.65M
Net Cash / Share 4.61
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -22.95%
ROE -38.79%
ROIC -37.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(44.23% upside)
Current: $17.16
Target: 24.75
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-67.48-62.88-36.08-24.54-19.99
Net Income-63.14-60.45-35.43-27.56-22.63
Shares Outstanding41.9535.1923.2418.709.93
Earnings Per Share-1.51-1.72-1.52-1.47-2.28
Operating Cash Flow-54.76-48.66-28.44-25.35-17.93
Capital Expenditures-----0.06
Free Cash Flow-54.76-48.66-28.44-25.35-17.99
Cash & Equivalents23717993.1567.7985.75
Total Debt7.507.507.107.32-
Net Cash / Debt22917186.0560.4785.75
Book Value21916179.8756.8882.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kura Oncology, Inc.
Country United States
Employees 62
CEO Troy E. Wilson

Stock Information

Ticker Symbol KURA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KURA


Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.